These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 37788351)
1. Study on the Multimodal Anticancer Mechanism of Ru(II)/Ir(III) Complexes Bearing a Poly(ADP-ribose) Polymerase 1 Inhibitor. Yang Y; Gao Y; Sun Y; Zhao J; Gou S J Med Chem; 2023 Oct; 66(19):13731-13745. PubMed ID: 37788351 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization, anticancer efficacy evaluation of ruthenium(II) and iridium(III) polypyridyl complexes toward A549 cells. Liang L; Yang Y; Liu H; Yuan F; Yuan Y; Li W; Huang C; Chen J; Liu Y J Biol Inorg Chem; 2023 Jun; 28(4):421-437. PubMed ID: 37097484 [TBL] [Abstract][Full Text] [Related]
3. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents. Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192 [TBL] [Abstract][Full Text] [Related]
4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features. Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963 [TBL] [Abstract][Full Text] [Related]
5. Anticancer effect evaluation in vitro and in vivo of iridium(III) polypyridyl complexes targeting DNA and mitochondria. Zhang H; Tian L; Xiao R; Zhou Y; Zhang Y; Hao J; Liu Y; Wang J Bioorg Chem; 2021 Oct; 115():105290. PubMed ID: 34426145 [TBL] [Abstract][Full Text] [Related]
6. DNA binding and evaluation of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes. Zhang Y; Zhou Y; Zhang H; Tian L; Hao J; Yuan Y; Li W; Liu Y J Inorg Biochem; 2021 Nov; 224():111580. PubMed ID: 34438219 [TBL] [Abstract][Full Text] [Related]
7. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents. Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046 [TBL] [Abstract][Full Text] [Related]
8. Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells. Pavlović M; Tadić A; Gligorijević N; Poljarević J; Petrović T; Dojčinović B; Savić A; Radulović S; Grgurić-Šipka S; Aranđelović S J Inorg Biochem; 2020 Sep; 210():111155. PubMed ID: 32768729 [TBL] [Abstract][Full Text] [Related]
9. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes. Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation of novel iridium(III) complexes targeting mitochondria toward melanoma B16 cells. Yuan Y; Zhang Y; Chen J; Huang C; Liu H; Li W; Liang L; Wang Y; Liu Y Eur J Med Chem; 2023 Feb; 247():115046. PubMed ID: 36577214 [TBL] [Abstract][Full Text] [Related]
12. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes. Ludwig G; Mojić M; Bulatović M; Mijatović S; Maksimović-Ivanić D; Steinborn D; Kaluđerović GN Anticancer Agents Med Chem; 2016; 16(11):1455-1460. PubMed ID: 26510901 [TBL] [Abstract][Full Text] [Related]
13. Rhodamine-modified fluorescent half-sandwich iridium and ruthenium complexes: potential application as bioimaging and anticancer agents. Ma W; Guo L; Tian Z; Zhang S; He X; Li J; Yang Y; Liu Z Dalton Trans; 2019 Apr; 48(15):4788-4793. PubMed ID: 30892340 [TBL] [Abstract][Full Text] [Related]
14. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors. de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342 [TBL] [Abstract][Full Text] [Related]
15. Hetero-Bis-Conjugation of Bioactive Molecules to Half-Sandwich Ruthenium(II) and Iridium(III) Complexes Provides Synergic Effects in Cancer Cell Cytotoxicity. Biancalana L; Kostrhunova H; Batchelor LK; Hadiji M; Degano I; Pampaloni G; Zacchini S; Dyson PJ; Brabec V; Marchetti F Inorg Chem; 2021 Jul; 60(13):9529-9541. PubMed ID: 34156246 [TBL] [Abstract][Full Text] [Related]
16. Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer and antibacterial agents to induce both autophagy and apoptosis. Chen BB; Pan NL; Liao JX; Huang MY; Jiang DC; Wang JJ; Qiu HJ; Chen JX; Li L; Sun J J Inorg Biochem; 2021 Jun; 219():111450. PubMed ID: 33826973 [TBL] [Abstract][Full Text] [Related]
17. Ferrocene-modified half-sandwich iridium(III) and ruthenium(II) propionylhydrazone complexes and anticancer application. Ji C; Dong R; Zhang P; Tao R; Wang X; Dai Q; Liu X; Yuan XA; Zhang S; Yue M; Liu Z J Inorg Biochem; 2024 Aug; 257():112586. PubMed ID: 38728860 [TBL] [Abstract][Full Text] [Related]
18. Increasing Anticancer Activity with Phosphine Ligation in Zwitterionic Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes. Hu X; Guo L; Liu M; Zhang Q; Gong Y; Sun M; Feng S; Xu Y; Liu Y; Liu Z Inorg Chem; 2022 Dec; 61(49):20008-20025. PubMed ID: 36426422 [TBL] [Abstract][Full Text] [Related]
19. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity. Wang Z; Qian H; Yiu SM; Sun J; Zhu G J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912 [TBL] [Abstract][Full Text] [Related]